ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) shares reached a new 52-week low during mid-day trading on Tuesday after Guggenheim lowered their price target on the stock from $30.00 to $28.00. Guggenheim currently has a buy rating on the stock. ArriVent BioPharma traded as low as $10.91 and last traded at $10.96, with a volume of 92,698 shares trading hands. The stock had previously closed at $11.56.
Several other analysts have also recently weighed in on the stock. BTIG Research reiterated a "buy" rating and issued a $29.00 price target on shares of ArriVent BioPharma in a report on Friday, October 16th. Truist Financial upped their price objective on shares of ArriVent BioPharma from $21.00 to $24.00 and gave the stock a "buy" rating in a report on Tuesday, November 10th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of ArriVent BioPharma in a research report on Thursday. Oppenheimer reaffirmed an "outperform" rating and set a $25.00 target price on shares of ArriVent BioPharma in a research note on Monday, October 26th. Finally, Citigroup reduced their price target on shares of ArriVent BioPharma from $40.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, October 7th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $24.67.
View Our Latest Stock Analysis on ArriVent BioPharma
Institutional Investors Weigh In On ArriVent BioPharma
Hedge funds and other institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. increased its stake in shares of ArriVent BioPharma by 29.7% during the third quarter. Goldman Sachs Group Inc. now owns 1,107,094 shares of the company's stock valued at $33,523,000 after purchasing an additional 253,371 shares in the last quarter. Entropy Technologies LP purchased a new position in shares of ArriVent BioPharma during the third quarter valued at approximately $478,000. Jump Financial LLC lifted its holdings in shares of ArriVent BioPharma by 173.5% during the third quarter. Jump Financial LLC now owns 81,067 shares of the company's stock valued at $2,455,000 after purchasing an additional 51,423 shares during the last quarter. Alps Advisors Inc. boosted its position in shares of ArriVent BioPharma by 38.7% in the 3rd quarter. Alps Advisors Inc. now owns 65,315 shares of the company's stock worth $1,978,000 after purchasing an additional 18,241 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of ArriVent BioPharma in the 3rd quarter worth approximately $76,000. Hedge funds and other institutional investors own 9.48% of the company's stock.
ArriVent BioPharma Stock Performance
The business has a 50-day moving average price of $20.97 and a 200 day moving average price of $26.35. The stock has a market capitalization of $577.71 million, a P/E ratio of -3.10 and a beta of 1.66.
ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.24. The company had revenue of $5.00 million during the quarter, compared to the consensus estimate of $0.80 million. As a group, research analysts forecast that ArriVent BioPharma, Inc. will post -3.81 earnings per share for the current fiscal year.
ArriVent BioPharma Company Profile
(
Get Free Report)
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing medicines for people with cancer. The company advances therapies intended to address significant unmet medical needs, with an emphasis on treatments that may offer new options for patients with difficult-to-treat tumors. Its lead clinical program is furmonertinib, an oral targeted therapy being studied for non-small cell lung cancer with certain epidermal growth factor receptor (EGFR) mutations, including exon 20 insertion mutations.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ArriVent BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ArriVent BioPharma wasn't on the list.
While ArriVent BioPharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.